Comprehensive Identification of Mutational Cancer Driver Genes Across 12 Tumor Types

Overview

Journal Sci Rep

Specialty Science

Date 2013 Oct 3

PMID 24084849

Citations 305

Authors

David Tamborero

Abel Gonzalez-Perez

Christian Perez-Llamas

Jordi Deu-Pons

Cyriac Kandoth

Juri Reimand

Michael S Lawrence

Gad Getz

Gary D Bader

Li Ding

Nuria Lopez-Bigas

Affiliations

Soon will be listed here.

Abstract

With the ability to fully sequence tumor genomes/exomes, the quest for cancer driver genes can now be undertaken in an unbiased manner. However, obtaining a complete catalog of cancer genes is difficult due to the heterogeneous molecular nature of the disease and the limitations of available computational methods. Here we show that the combination of complementary methods allows identifying a comprehensive and reliable list of cancer driver genes. We provide a list of 291 high-confidence cancer driver genes acting on 3,205 tumors from 12 different cancer types. Among those genes, some have not been previously identified as cancer drivers and 16 have clear preference to sustain mutations in one specific tumor type. The novel driver candidates complement our current picture of the emergence of these diseases. In summary, the catalog of driver genes and the methodology presented here open new avenues to better understand the mechanisms of tumorigenesis.

Citing Articles

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6.

Bai M, Wang R, Huang C, Zhong R, Jiang N, Fu W Sci Rep. 2024; 14(1):29661.

PMID: 39613883 PMC: 11607416. DOI: 10.1038/s41598-024-81392-0.

Whole‑exome sequencing insights into synchronous bilateral breast cancer with discordant molecular subtypes.

Hu S, Gao B, Li Z, Yuan Y Oncol Lett. 2024; 28(6):595.

PMID: 39430730 PMC: 11487496. DOI: 10.3892/ol.2024.14728.

Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies.

Echeverria-Garces G, Ramos-Medina M, Gonzalez A, Vargas R, Cabrera-Andrade A, Armendariz-Castillo I Heliyon. 2024; 10(17):e37488.

PMID: 39296198 PMC: 11409134. DOI: 10.1016/j.heliyon.2024.e37488.

Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy.

Mai Z, Kongjia L, Wang X, Xie X, Pang L, Yang H Cancer Immunol Immunother. 2024; 73(11):225.

PMID: 39235488 PMC: 11377381. DOI: 10.1007/s00262-024-03798-z.

ECD-CDGI: An efficient energy-constrained diffusion model for cancer driver gene identification.

Wang T, Zhuo L, Chen Y, Fu X, Zeng X, Zou Q PLoS Comput Biol. 2024; 20(8):e1012400.

PMID: 39213450 PMC: 11392234. DOI: 10.1371/journal.pcbi.1012400.

References

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

Reimand J, Bader G . Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol. 2013; 9:637. PMC: 3564258. DOI: 10.1038/msb.2012.68. View

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

Tabin C, Bradley S, Bargmann C, Weinberg R, Papageorge A, Scolnick E . Mechanism of activation of a human oncogene. Nature. 1982; 300(5888):143-9. DOI: 10.1038/300143a0. View

Artez A, Bernabe R, Eerola I, Hemsley F, Jennings J, Kerr D . International network of cancer genome projects. Nature. 2010; 464(7291):993-8. PMC: 2902243. DOI: 10.1038/nature08987. View

Cerami E, Gross B, Demir E, Rodchenkov I, Babur O, Anwar N . Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 2010; 39(Database issue):D685-90. PMC: 3013659. DOI: 10.1093/nar/gkq1039. View

Vogelmann R, Nguyen-Tat M, Giehl K, Adler G, Wedlich D, Menke A . TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci. 2005; 118(Pt 20):4901-12. DOI: 10.1242/jcs.02594. View

Sasaki T, Irie-Sasaki J, Horie Y, Bachmaier K, Fata J, Li M . Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature. 2000; 406(6798):897-902. DOI: 10.1038/35022585. View

10.

Tamborero D, Gonzalez-Perez A, Lopez-Bigas N . OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics. 2013; 29(18):2238-44. DOI: 10.1093/bioinformatics/btt395. View

11.

Kumar A, Redondo-Munoz J, Perez-Garcia V, Cortes I, Chagoyen M, Carrera A . Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival. Mol Cell Biol. 2011; 31(10):2122-33. PMC: 3133359. DOI: 10.1128/MCB.01313-10. View

12.

Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder M, Jene-Sanz A . IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods. 2013; 10(11):1081-2. PMC: 5758042. DOI: 10.1038/nmeth.2642. View

13.

Marques M, Kumar A, Cortes I, Gonzalez-Garcia A, Hernandez C, Moreno-Ortiz M . Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol. 2008; 28(8):2803-14. PMC: 2293125. DOI: 10.1128/MCB.01786-07. View

14.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

15.

Ng P, Henikoff S . SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003; 31(13):3812-4. PMC: 168916. DOI: 10.1093/nar/gkg509. View

16.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

17.

Tamborero D, Lopez-Bigas N, Gonzalez-Perez A . Oncodrive-CIS: a method to reveal likely driver genes based on the impact of their copy number changes on expression. PLoS One. 2013; 8(2):e55489. PMC: 3568145. DOI: 10.1371/journal.pone.0055489. View

18.

Gonzalez-Perez A, Lopez-Bigas N . Functional impact bias reveals cancer drivers. Nucleic Acids Res. 2012; 40(21):e169. PMC: 3505979. DOI: 10.1093/nar/gks743. View

19.

Vogelstein B, Papadopoulos N, Velculescu V, Zhou S, Diaz Jr L, Kinzler K . Cancer genome landscapes. Science. 2013; 339(6127):1546-58. PMC: 3749880. DOI: 10.1126/science.1235122. View

20.

Imamura Y, Sakamoto S, Endo T, Utsumi T, Fuse M, Suyama T . FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS One. 2012; 7(8):e42456. PMC: 3411739. DOI: 10.1371/journal.pone.0042456. View